Acute stroke Circulatory System Stroke, not specified as haemorrhage or infarction
Conditions
Interventions
Patients will be randomised to receive either Candesartan (intervention group) or placebo. After four weeks of double blind treatment, patients will have their clinic blood pressure treated to target
Sponsors
City Hospitals Sunderland NHS Foundation Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Clinical diagnosis of acute ischaemic stroke within 72 hours of symptom onset (proven on CT imaging). 2. Medically stable with no evidence of acute infection and not receiving antibiotic therapy. 3. Neurologically stable with no progression on NIHSS. 4. Able to swallow safely and able to tolerate unthickened oral fluids without risk of aspiration. 5. Mean blood pressure in the unaffected arm >120/70 from three readings taken within one hour at twenty minute intervals using a calibrated Omron M5-1 BP monitor.
Exclusion criteria
Exclusion criteria: 1. Previous severe disability (Modified Rankin Score greater to or equal to 3). 2. Nursing home resident. 3. Previous history of congestive cardiad failure requiring treatment with an ACE inhibitor or Angiotensin Receptor Blocker (ARB). 4. Renal impairment (defined serum creatinine >200 umol/l). 5. Women of child bearing potential. 6. Minors aged less than 18. 7. History of evidence of dementia without capacity for consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the safety of the proposed methodology and how many primary end points (combined or single) may be configured for evaluation in a large randomised controlled trial. | — |
Secondary
| Measure | Time frame |
|---|---|
| The early effects of Candesartan upon blood pressure following stroke when used within an explicit evidence based protocol. | — |
Countries
United Kingdom
Outcome results
None listed